AC Immune SA (ACIU) vs Bicycle Therapeutics (BCYC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AC Immune SA (ACIU) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 27.6% versus a loss of 53.9%. Over five years, ACIU leads with a -58.7% price change compared with -93.6% for BCYC. Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $253.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | BCYC |
|---|---|---|
| Share price | $2.55 | $3.81 |
| Market cap | $253.54M | $266.67M |
| 1-day change | -0.78% | +2.14% |
| YTD return | -18.79% | -46.19% |
| 1-year return | -27.56% | -53.87% |
| 5-year return | -58.74% | -93.57% |
| Forward P/E | 4.29 | — |
| EPS (TTM) | $-0.54 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $9.16 |
| 52-week low | $2.10 | $3.33 |
| Distance from 52-week high | -36.25% | -58.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +234.12% | +149.34% |
| Average volume | 202.76K | 391.03K |
| Shares outstanding | 99.43M | 50.55M |
| Employees | 90 | 288 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed BCYC by 26.3 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
ACIU vs BCYC FAQ
Which is bigger, AC Immune SA or Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $253.54M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or BCYC?
ACIU returned -27.56% over the past 12 months, compared with -53.87% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Bicycle Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.